<DOC>
	<DOCNO>NCT01932333</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics ( body study medication ) pharmacodynamics ( study action effect study medication body ) single- multiple , escalate oral dos JNJ-40411813 .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Pharmacokinetics Pharmacodynamics JNJ-40411813 Male Female Elderly Patients</brief_title>
	<detailed_description>This double-blind ( neither physician participant know treatment participant receives ) , randomize ( study medication assign chance ) , placebo-controlled ( inactive substance compare medication test whether medication real effect clinical study ) , single- multiple ascend dose study . This study consist 3 phase : screening phase , treatment phase , follow-up phase . This study conduct 2 cohort ( group ) ( Cohort 1 : JNJ-40411813 50 mg Cohort 2 : JNJ-40411813 100 mg ) cohort consist 2 period ( Period 1 : single dose Period 2 : multiple dos ) . Approximately 36 participant enrol study ( 18 participant enrol cohort ) receive JNJ-40411813 placebo 2:1 ratio . If safety/tolerability pharmacokinetic result profile favorable single dose JNJ-40411813 , multiple dose administration follow . Safety evaluate assessment adverse event , vital sign , schellong test ( test circulatory function ) , 12-lead electrocardiogram , physical examination , neurological examination ( measure mental status , motor examination , reflex , sensory , gait cranial nerve ) , vertigo ( giddiness ) symptom , clinical laboratory test monitor throughout study . The total duration study participation participant 9 week .</detailed_description>
	<criteria>Female participant must postmenopausal least 12 month Body mass index ( BMI ) 18 33 kg/m2 ( BMI calculate weight [ kilogram ] divide square height [ meter ] ) Clinically significant abnormal value laboratory test abnormal physical examination Significant history current significant unstable medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematological disease , bronchospastic respiratory disease , dyspnea ( difficulty breathe ) , diabetes mellitus , thyroid disease , infection Significant history current psychiatric neurological illness Serology positive hepatitis B surface antigen , hepatitis C antibodies HIV antibody screen Positive urine screen drug abuse positive alcohol breath test screen administration study medication Only use prescription medication know potent CYP3A4 inhibitor inducer within 2 week start study medication</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>JNJ-40411813</keyword>
	<keyword>Positive allosteric modulator</keyword>
</DOC>